{"title":"American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.","authors":"Alexandra Kibble","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 10","pages":"673-6"},"PeriodicalIF":0.0000,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The 240th National Meeting of the American Chemical Society, held in Boston, included topics covering new therapeutic research. This conference report highlights selected presentations on (S)-adenosylhomocysteine (AHCY) inhibitors for the treatment of Alzheimer's disease, 2,4-diphenyl-1H-imidazole analogs as cannabinoid CB2 agonists for the treatment of pain, checkpoint kinase 1 (Chk1) and Aurora kinase B as therapeutic targets for cancer treatment, pyridylmethylthio derivatives as VEGFR2 inhibitors, and Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders. Investigational drugs discussed include L-002259713 (Merck & Co), AZD-1480 (AstraZeneca), CYT-387 (YM Biosciences) and ruxolitinib (Incyte).
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
